After receiving feedback from members, the association submitted comments to CMS on the proposed rule that includes implementation of the Joe Fiandra Access to Home Infusion Act as well as steps in the agency’s continued focus on fraud and abuse. Read the comments.
NHIA commends CMS for listening to stakeholders and deciding not to move forward at this time with the proposed changes to HCPCS codes and billing units for immune globulin products.
https://doi.org/10.70776/ECBT6827
Danell Haines, PhD — Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC — National Home Infusion Association | Jennifer Charron, RN, MSN, MBA — National Home Infusion Association
Home administered intravenous immune globulin (IVIG) is well established as a patient-centered alternative to facility-based infusion. Safe delivery of home based IVIG relies on appropriate infusion support, which may include an infusion nurse to prepare and administer therapy, monitor the patient’s response, perform vascular access care, provide patient education, coordinate care, and communicate with the interdisciplinary team.
https://doi.org/10.70776/KXON8746
Danell Haines, PhD — Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC — National Home Infusion Association | Jennifer Charron, RN, MSN, MBA — National Home Infusion Association
Home infusion anti-infective therapy is an important component of post-acute care, allowing patients to transition more quickly from facility-based treatment to home-based intravenous therapy. The patient onboarding phase is a critical and resource-intensive period that requires coordinated activities by nurses and pharmacists, including clinical assessment, care planning, medication preparation, patient education, documentation, and communication with prescribers and other care team members. Home infusion providers invest professional time toward patient onboarding before payment begins, and a significant proportion of referred patients may not ultimately receive billable home infusion services. Limited evidence exists quantifying the combined nursing and pharmacist time required to onboard home infusion anti-infective patients. This study evaluated the time and task distribution associated with nurse and pharmacist tasks during patient onboarding activities for home infusion anti-infective therapy.
https://doi.org/10.70776/BVXP9818
Danell Haines, PhD — Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC — National Home Infusion Association | Jennifer Charron, RN, MSN, MBA — National Home Infusion Association
Home infusion therapy is an established and growing model of care that allows patients to receive complex infusion treatments in the home setting. Successful initiation of home infusion therapy requires coordinated nurse, pharmacy, and prescriber involvement, particularly during the transition from referral to the first home visits. Although home infusion nurses perform a wide range of clinical and coordination activities, limited published data describe the time required to deliver these services or how nurse workload varies by therapy type. This multicenter descriptive observational time study quantified home infusion nurse time and task distribution during therapy initiation for anti-infective and intravenous monoclonal antibody therapies.
The National Home Infusion Foundation’s Wellness Challenge is returning this September, and we’re excited to invite your organization to sponsor a team and make a meaningful impact on our industry!
This proposal to modify the criteria for the use of an infusion pump should not be viewed as a solution to the broader access challenges facing Medicare beneficiaries who could safely receive infusion therapy at home.
NHIA submitted comments to CMS on a new proposed rule on interoperability and prior authorization for drugs. While NHIA is mostly supportive of standardizing prior authorization (PA) processes for Medicare-covered drugs, it wants CMS to know that home infusion may not fit neatly into processes designed for medical and pharmacy benefits.
NHIA strongly opposes CMS’s proposed HCPCS coding and billing unit changes for immune globulin products, arguing that the changes would create significant administrative, operational, reimbursement, and patient care challenges without providing meaningful clinical or financial benefit.
The National Home Infusion Foundation (NHIF) welcomes the 2026-2027 Board of Directors.
Last week concluded the 2026 National Home Infusion Association Annual Conference (NHIA 2026), which convened the largest gathering dedicated to the home and alternate site infusion industry in Denver, Colorado.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
The National Home Infusion Foundation (NHIF) announces the winner and honorable mention for its Outstanding Abstract Achievement Award for 2026.
The National Home Infusion Association has announced the finalists for its 2026 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
The National Home Infusion Association (NHIA) is pleased to announce the 2026 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The National Home Infusion Foundation (NHIF) is proud to announce Barbara Petroff, MS, RPh, BCSCP, CAC, CSPP, IgCP, FNHIA, FASHP as the recipient of the 2026 Women in Leadership Award.
https://doi.org/10.70776/TJLU1217
Jennifer Zhao PharmD, Johns Hopkins Care at Home | Tricia Schneider PharmD, MBA, Johns Hopkins Care at Home | Krista Decker RPh, MSQA, Johns Hopkins Care at Home
Drug utilization review (DUR) systems are important for ensuring medication safety by identifying medication-related issues, such as Drug-Drug interactions and therapy duplications. While DUR
alerts support clinical decision-making, excessive or clinically irrelevant alerts can lead to alert fatigue. This can potentially cause pharmacists to overlook crucial warnings and jeopardize patient safety.
After receiving feedback from members, the association submitted comments to CMS on the proposed rule that includes implementation of the Joe Fiandra Access to Home Infusion Act as well as steps in the agency’s continued focus on fraud and abuse. Read the comments.
NHIA commends CMS for listening to stakeholders and deciding not to move forward at this time with the proposed changes to HCPCS codes and billing units for immune globulin products.
https://doi.org/10.70776/ECBT6827
Danell Haines, PhD — Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC — National Home Infusion Association | Jennifer Charron, RN, MSN, MBA — National Home Infusion Association
Home administered intravenous immune globulin (IVIG) is well established as a patient-centered alternative to facility-based infusion. Safe delivery of home based IVIG relies on appropriate infusion support, which may include an infusion nurse to prepare and administer therapy, monitor the patient’s response, perform vascular access care, provide patient education, coordinate care, and communicate with the interdisciplinary team.
https://doi.org/10.70776/KXON8746
Danell Haines, PhD — Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC — National Home Infusion Association | Jennifer Charron, RN, MSN, MBA — National Home Infusion Association
Home infusion anti-infective therapy is an important component of post-acute care, allowing patients to transition more quickly from facility-based treatment to home-based intravenous therapy. The patient onboarding phase is a critical and resource-intensive period that requires coordinated activities by nurses and pharmacists, including clinical assessment, care planning, medication preparation, patient education, documentation, and communication with prescribers and other care team members. Home infusion providers invest professional time toward patient onboarding before payment begins, and a significant proportion of referred patients may not ultimately receive billable home infusion services. Limited evidence exists quantifying the combined nursing and pharmacist time required to onboard home infusion anti-infective patients. This study evaluated the time and task distribution associated with nurse and pharmacist tasks during patient onboarding activities for home infusion anti-infective therapy.
https://doi.org/10.70776/BVXP9818
Danell Haines, PhD — Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC — National Home Infusion Association | Jennifer Charron, RN, MSN, MBA — National Home Infusion Association
Home infusion therapy is an established and growing model of care that allows patients to receive complex infusion treatments in the home setting. Successful initiation of home infusion therapy requires coordinated nurse, pharmacy, and prescriber involvement, particularly during the transition from referral to the first home visits. Although home infusion nurses perform a wide range of clinical and coordination activities, limited published data describe the time required to deliver these services or how nurse workload varies by therapy type. This multicenter descriptive observational time study quantified home infusion nurse time and task distribution during therapy initiation for anti-infective and intravenous monoclonal antibody therapies.
The National Home Infusion Foundation’s Wellness Challenge is returning this September, and we’re excited to invite your organization to sponsor a team and make a meaningful impact on our industry!
This proposal to modify the criteria for the use of an infusion pump should not be viewed as a solution to the broader access challenges facing Medicare beneficiaries who could safely receive infusion therapy at home.
NHIA submitted comments to CMS on a new proposed rule on interoperability and prior authorization for drugs. While NHIA is mostly supportive of standardizing prior authorization (PA) processes for Medicare-covered drugs, it wants CMS to know that home infusion may not fit neatly into processes designed for medical and pharmacy benefits.
NHIA strongly opposes CMS’s proposed HCPCS coding and billing unit changes for immune globulin products, arguing that the changes would create significant administrative, operational, reimbursement, and patient care challenges without providing meaningful clinical or financial benefit.
The National Home Infusion Foundation (NHIF) welcomes the 2026-2027 Board of Directors.
Last week concluded the 2026 National Home Infusion Association Annual Conference (NHIA 2026), which convened the largest gathering dedicated to the home and alternate site infusion industry in Denver, Colorado.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
The National Home Infusion Foundation (NHIF) announces the winner and honorable mention for its Outstanding Abstract Achievement Award for 2026.
The National Home Infusion Association has announced the finalists for its 2026 Exhibitor Innovation Award. The award recognizes groundbreaking products or services that advance the home and alternate site infusion industry.
The National Home Infusion Association (NHIA) is pleased to announce the 2026 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The National Home Infusion Foundation (NHIF) is proud to announce Barbara Petroff, MS, RPh, BCSCP, CAC, CSPP, IgCP, FNHIA, FASHP as the recipient of the 2026 Women in Leadership Award.
https://doi.org/10.70776/TJLU1217
Jennifer Zhao PharmD, Johns Hopkins Care at Home | Tricia Schneider PharmD, MBA, Johns Hopkins Care at Home | Krista Decker RPh, MSQA, Johns Hopkins Care at Home
Drug utilization review (DUR) systems are important for ensuring medication safety by identifying medication-related issues, such as Drug-Drug interactions and therapy duplications. While DUR
alerts support clinical decision-making, excessive or clinically irrelevant alerts can lead to alert fatigue. This can potentially cause pharmacists to overlook crucial warnings and jeopardize patient safety.
